Safety and Pharmacodynamics of SHR-1707 in Alzheimer's Disease Patients

This study tests the safety and early effectiveness of a new drug called SHR-1707 for people in the early stages of Alzheimer's disease. SHR-1707 targets amyloid plaques — the abnormal protein deposits in the brain that are a key feature of Alzheimer's. **You may be eligible if...** - You are 50–85 years old - You have been diagnosed with mild cognitive impairment (early memory problems) or mild Alzheimer's disease - A PET brain scan has confirmed the presence of amyloid plaques - Your depression score is low (HAMD-17 ≤10) - Your BMI is between 18 and 32, and you weigh between 45–100 kg **You may NOT be eligible if...** - You have moderate or severe Alzheimer's disease - You do not have confirmed amyloid changes on brain PET scan - You have significant depression or other serious psychiatric conditions - You are outside the weight or BMI range Talk to your doctor to see if this trial is right for you.